You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA193
  • Published:  28 July 2010
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal

Back to past appeals page

  • Leukaemia (chronic lymphocytic, relapsed) - rituximab: background information on the technology appraisal

  • Leukaemia (chronic lymphocytic, relapsed) - rituximab: notice of appeal

  • Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal announcement

  • Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal decision


This page was last updated: 16 August 2010

Back to top